<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04605302</url>
  </required_header>
  <id_info>
    <org_study_id>UMASS-01</org_study_id>
    <nct_id>NCT04605302</nct_id>
  </id_info>
  <brief_title>Comparative Study of MCCE With/Without Tether vs Conventional Upper Endoscopy in Patients With Upper Abdominal Symptoms</brief_title>
  <official_title>A Prospective Single Blinded, Pilot Study, Comparing a Magnetically Controlled Capsule With or Without a Tether (MCC or MCC-T) With Conventional Upper Endoscopy for the Diagnosis of Patients With Upper Abdominal Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AnX Robotica Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AnX Robotica Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective single blinded, tandem study, comparing a magnetically controlled capsule with&#xD;
      or without a tether (MCC or MCC-T) with conventional upper endoscopy for the diagnosis of&#xD;
      patients with upper abdominal symptoms.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the US patients commonly undergo esophagogastroduodenoscopy (EGD) for upper abdominal&#xD;
      symptoms to try to resolve whether they have gastroesophageal reflux disease or functional&#xD;
      dyspepsia, if they are older than the age of 60 with symptoms, or have alarm symptoms such as&#xD;
      unexplained weight loss, persistent nausea and vomiting or if they have symptoms that are&#xD;
      refractory to acid suppression therapy. Given the increasing burden of digestive disease in&#xD;
      the US, the use of EGD is increasing in volume nationwide. EGD usually requires either&#xD;
      conscious sedation or monitored anesthesia sedation, which has put an additional cost burden&#xD;
      on the healthcare system. Since MCC or MCC-T does not require sedation, it offers an&#xD;
      attractive option for both patients and clinicians alike.&#xD;
&#xD;
      The aim of this study is to compare in the same patient the accuracy of the MCC and MCC-T and&#xD;
      EGD in patients presenting with upper abdominal symptoms.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 12, 2021</start_date>
  <completion_date type="Anticipated">April 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Tandem study</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Patient blinded to MCC results. EGD assessor blinded to MCC results.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of lesions</measure>
    <time_frame>2 days</time_frame>
    <description>Number of lesions found by MCC/MCC-T versus EGD</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of adverse events</measure>
    <time_frame>2 days</time_frame>
    <description>Occurrence and severity of adverse event related to MCC/MCC-T procedure versus EGD procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction score</measure>
    <time_frame>2 days</time_frame>
    <description>Patient acceptance of MCC/MCC-T versus EGD (scale of 1 to 10 when 1 is the lowest and 10 is the highest score)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Upper Gastrointestinal Symptoms</condition>
  <arm_group>
    <arm_group_label>Single Arm Tandem Study</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients are assigned to swallow a magnetically controlled capsule first then undergo standard gastroscopy</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MCC/MCC-T</intervention_name>
    <description>Magnetically controlled capsule endoscopy (MCC), with or without tether, is used to visualize the upper gastrointestinal tract</description>
    <arm_group_label>Single Arm Tandem Study</arm_group_label>
    <other_name>Magnetic controlled capsule endoscopy with/without tether</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Standard gastroscopy</intervention_name>
    <description>Diagnostic endoscopic procedure that visualizes the upper part of the gastrointestinal tract down to the duodenum</description>
    <arm_group_label>Single Arm Tandem Study</arm_group_label>
    <other_name>EGD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient is able to provide informed consent&#xD;
&#xD;
          2. Patient has appropriate indications for EGD including symptoms of, but not limited to&#xD;
             upper abdominal pain, acid reflux, heartburn, iron deficiency anemia, weight loss,&#xD;
             bloating, belching, nausea, vomiting and atypical chest pain.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient with dysphagia.&#xD;
&#xD;
          2. Patient with previous intestinal surgery.&#xD;
&#xD;
          3. Patient with Crohn's disease or other potential obstructive conditions, unless there&#xD;
             is a recent CTE, MRE or patency capsule performed to exclude an obstructive lesion&#xD;
             that may retain the capsule.&#xD;
&#xD;
          4. Female patient who is pregnant.&#xD;
&#xD;
          5. Patient with implanted medical device that would be potentially affected by magnets or&#xD;
             radiofrequency emissions (e.g., pacemakers, implanted cardiac defibrillators).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David R Cave, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Massachusetts, Worcester</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Anne Foley</last_name>
    <phone>7744424098</phone>
    <email>anne.foley@umassmemorial.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>David R Cave, MD, PhD</last_name>
    <phone>7744424098</phone>
    <email>david.cave@umassmemorial.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Massachusetts Medical School</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne Foley</last_name>
      <phone>774-442-4098</phone>
      <email>anne.foley@umassmemorial.org</email>
    </contact>
    <investigator>
      <last_name>David R Cave, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 8, 2020</study_first_submitted>
  <study_first_submitted_qc>October 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 28, 2020</study_first_posted>
  <last_update_submitted>February 9, 2021</last_update_submitted>
  <last_update_submitted_qc>February 9, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 10, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

